ReviewJMIR dermatology2026
Beta-Alanine and Aquagenic Pruritus: Proposed Neuroimmune Mechanism.
Review in JMIR dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unlabelled: Aquagenic pruritus (AP) is a rare itch disorder with limited effective treatments, and emerging clinical observations suggest that oral β-alanine may reduce symptoms. The purpose of this viewpoint is to propose a biologically plausible mechanism through which β-alanine may alleviate primary AP. We reviewed published case reports and patient-reported survey data describing β-alanine use in AP and integrated these clinical observations with experimental data on MAS-related G protein-coupled receptor D (MrgprD)-expressing sensory neurons and their role in mast-cell regulation. Published case reports describe marked improvement in water-induced pruritus following prophylactic oral β-alanine administration, and a recent survey of patients with idiopathic AP reported substantial symptom relief among β-alanine users. Preclinical data indicate that MrgprD-neuronal glutamate release suppresses mast cell hyperresponsiveness, suggesting a potential pathway for the observed antipruritic effect. Additional mechanisms, including β-alanine metabolism to carnosine and its potential mast cell-stabilizing effects, may also contribute. β-alanine may act through modulation of a nonhistaminergic neuroimmune circuit and represents a promising therapeutic candidate for further investigation in AP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.